CDK4/6 Inhibitor Combos Miss Survival Goal in Metastatic Breast Cancer Subset
No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations with initial treatment for HR-positive, HER2-negative metastatic breast cancer.